Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Klement, RJ; Abbasi-Senger, N; Adebahr, S; Alheid, H; Allgaeuer, M; Becker, G; Blanck, O; Boda-Heggemann, J; Brunner, T; Duma, M; Eble, MJ; Ernst, I; Gerum, S; Habermehl, D; Hass, P; Henkenberens, C; Hildebrandt, G; Imhoff, D; Kahl, H; Klass, ND; Krempien, R; Lewitzki, V; Lohaus, F; Ostheimer, C; Papachristofilou, A; Petersen, C; Rieber, J; Schneider, T; Schrade, E; Semrau, R; Wachter, S; Wittig, A; Guckenberger, M; Andratschke, N.
The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.
BMC Cancer. 2019; 19(1):173
Doi: 10.1186/s12885-019-5362-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The aim of this analysis was to model the effect of local control (LC) on overall survival (OS) in patients treated with stereotactic body radiotherapy (SBRT) for liver or lung metastases from colorectal cancer. METHODS: The analysis is based on pooled data from two retrospective SBRT databases for pulmonary and hepatic metastases from 27 centers from Germany and Switzerland. Only patients with metastases from colorectal cancer were considered to avoid histology as a confounding factor. An illness-death model was employed to model the relationship between LC and OS. RESULTS: Three hundred eighty-eight patients with 500 metastatic lesions (lung n = 209, liver n = 291) were included and analyzed. Median follow-up time for local recurrence assessment was 12.1 months. Ninety-nine patients with 112 lesions experienced local failure. Seventy-one of these patients died after local failure. Median survival time was 27.9 months in all patients and 25.4 months versus 30.6 months in patients with and without local failure after SBRT. The baseline risk of death after local failure exceeds the baseline risk of death without local failure at 10 months indicating better survival with LC. CONCLUSION: In CRC patients with lung or liver metastases, our findings suggest improved long-term OS by achieving metastatic disease control using SBRT in patients with a projected OS estimate of > 12 months.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Colorectal Neoplasms - mortality, radiotherapy, secondary
- Databases, Factual - administration & dosage
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Germany - administration & dosage
- Humans - administration & dosage
- Liver Neoplasms - mortality, radiotherapy, secondary
- Lung Neoplasms - mortality, radiotherapy, secondary
- Male - administration & dosage
- Middle Aged - administration & dosage
- Neoplasm Recurrence, Local - administration & dosage
- Radiosurgery - administration & dosage
- Retrospective Studies - administration & dosage
- Survival Analysis - administration & dosage
- Switzerland - administration & dosage
- Treatment Outcome - administration & dosage
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- Colorectal cancer
- Illness-death model
- Liver metastases
- Lung metastases
- Tumor control probability
- Stereotactic body radiation therapy